Pfizer and Mylan have agreed on terms by which Mylan may launch its generic version of Pfizer's Detrol LA (tolterodine tartrate) extended-release capsules, pending final approval by FDA.
Pfizer and Mylan have agreed on terms by which Mylan may launch its generic version of Pfizer’s Detrol LA (tolterodine tartrate) extended-release (ER) capsules, pending final approval by FDA.
Pfizer announced, in a Sept. 7, 2012, press release, that it has settled its litigation against Mylan and its subsidiary, Mylan Pharmaceuticals, regarding Pfizer’s patents covering Detrol LA (tolterodine tartrate) extended-release capsules. According to the agreement, Mylan may begin to sell its generic version on Jan. 1, 2014, subject to final approval by FDA.
Mylan had submitted an abbreviated new drug application (ANDA) for 2- and 4-mg tolterodine tartrate ER capsules, which are the generic version of Detrol LA. The drug is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. The agreement allows Mylan to launch the product as either an authorized generic or under its own ANDA, stated the company in a Sept. 7, 2012, press release. The agreements are subject to review by the US Federal Trade Commission and the US Department of Justice.
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.